GILD MEXC RealStocks
Own real GILD shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 21:57:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Gilead Sciences Inc. (GILD) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $167.96, with a market capitalization of $211.94B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $116.88 to $176.58. This page covers its latest market performance, valuation, price trends and company information.
$211.94B | |
$171.15 | |
$172.03 | |
$167.96 | |
$169.73 | |
3.21M | |
6.01M | |
-- | |
$176.58 | |
$116.88 | |
1.95% | |
12-31 |
Gilead Sciences Inc. (GILD) is trading at $168.89 in after-hours trading as of 2026-11-12 21:37:00, up 0.55% ($0.93) from the regular-session close of $167.96.
After-hours trading shows how investors are pricing GILD after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Gilead Sciences Inc. (GILD) moved from $167.47 to $167.96, representing a gain of 0.29% ($0.49).
The stock traded between $164.00 and $176.58 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 6.80 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 85.6%
GILD is currently trading at $167.96, placing it 85.6% of the way from its 52-week low of $116.88 to its 52-week high of $176.58. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 17,000 |
| CEO | Daniel Patrick O'Day |
| Founded | 1987 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Gilead Sciences Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Gilead Sciences Inc. (GILD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to GILD, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between GILD shares and USD.
GILD Shares to USD
1.00 GILD shares = 167.962 USD
Calculations are estimates based on the latest available price and are for reference only.